API Webinar💊 Q&A with @unseenvalue
Sir Promised 30 mins but ended up giving all of us more than 90 minutes 😁🙏
For unparalleled insights on the API industry🎥
https://t.co/x1U430JKFG
More from Intrinsic Compounding
More from Uvlearnings
Research in CDMO/APIs is never a slam dunk. It may take ages to yield results. CEP filings can be lumpy as a result. As I wrote last year (link below), Hikal has been consistently sacrificing operating profits for a sustainable future. Best is ahead 🎥 🍿
https://t.co/hItmOud8Pm
https://t.co/hItmOud8Pm
#Hikal has stepped up R&D in recent years. Next few years (capex & launches) should yield superior earnings. Wish them all the luck \U0001f44d
— Sajal Kapoor (@unseenvalue) September 26, 2020
D: invested and biased view for sure, but it was below 1x price to sales vs 12x price to sales for many chemicals and generic players. No reco!! pic.twitter.com/aqPUKbziHK
The comment from renowned investor was in a lighter vein. You ought to listen to the tone. He was spot on in comparing the capability and scale of two businesses, as both started around the same time - one could scale up, whilst other couldn't. Let's not read too much into it 🙂
In an example of how deeply ingrained misogyny is in the Indian system, billionaire investor Rakesh Jhunjhunwala asked the management of Jubilant Pharmova: \u201cHow can we be lower than the lady? We have to beat her,\u201d in a slighting reference to @kiranshaw.
— Dr. Kailashnath Koppikar (@koppik) June 26, 2021
https://t.co/1dkZ9JMLLr